National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 2967-2968 [2024-00774]
Download as PDF
<![CDATA[
2967
Federal Register / Vol. 89, No. 11 / Wednesday, January 17, 2024 / Notices
collection, the National Institute of
Health is collecting audience feedback
on a selection of survey questions and
research protocols. Parents/caregivers
and teens who are the same age as the
study cohort members but who are not
Study participants will review proposed
questions and give feedback on
questions’ clarity and acceptability.
Recommendations from these findings
help the ABCD Study team improve
their protocol for a more-successful data
collection.
Audience feedback activities will
include a mix of asynchronous and
scheduled, live data collection: webbased survey activities, virtual
discussion boards, individual
interviews, and discussions groups.
Assembling a cohort of audience
feedback participants who are familiar
with the ABCD Study and participate in
multiple data collection activities
minimizes the burden required to
familiarize new participants with the
purpose of the Study and the
expectations for audience feedback.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
172.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondent
Individuals
Individuals
Individuals
Individuals
Individuals
Individuals
Individuals
Individuals
Individuals
Individuals
Individuals
Average time
per response
(in hours)
Total annual
burden hour
(Parent/Caregiver Phone Screener) ..........................................
(Parent/Caregiver Consent) .......................................................
(Parent/Caregiver Permission for Teen Participation) ...............
(Teen Phone Screener) .............................................................
(Teen Assent or Consent) .........................................................
(Teen Web Survey) ...................................................................
(Parent/Caregiver Web Survey) ................................................
(Teen Virtual Group Discussion or Online Bulletin Board) .......
(Parent/Caregiver Virtual Interview) ..........................................
(Parent/Caregiver Online Bulletin Board) ..................................
(Parent/Caregiver ‘‘At-Home’’ Materials Review) ......................
72
15
36
72
36
36
15
36
15
15
15
1
1
1
1
1
2
2
2
1
1
1
5/60
5/60
5/60
5/60
10/60
30/60
30/60
1
30/60
1
15/60
6
1
3
6
6
36
15
72
8
15
4
Total ......................................................................................................
........................
450
..........................
172
Lanette A. Palmquist,
Project Clearance Liaison, National Institute
on Drug Abuse, National Institutes of Health.
[FR Doc. 2024–00760 Filed 1–16–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
lotter on DSK11XQN23PROD with NOTICES1
Number of
responses per
respondent
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2024–1 Phase I: Novel Diagnostic Biomarker
Discovery and Validation for Malaria and
VerDate Sep<11>2014
18:14 Jan 16, 2024
Jkt 262001
Select Neglected Tropical Diseases (NTDs)
(Topic 132).
Date: February 15, 2024.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G13A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Mairi Noverr, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G13A, Rockville, MD
20852, (240) 747–7530, mairi.noverr@
nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Small Business Innovation
Research (SBIR) Phase II Program Contract
Solicitation (PHS 2022–1) Topic 108—
Development of Rapid POC Diagnostics for
Treponema pallidum (N01).
Date: February 16, 2024.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G13A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Mairi Noverr, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G13A, Rockville, MD
20852, (240) 747–7530, mairi.noverr@
nih.gov.
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 11, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–00773 Filed 1–16–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
E:\FR\FM\17JAN1.SGM
17JAN1
2968
Federal Register / Vol. 89, No. 11 / Wednesday, January 17, 2024 / Notices
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2024–1 Phase I: Adjuvant Development for
Vaccines for Infectious and ImmuneMediated Diseases (Topic 128).
Date: February 8–9, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G22,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Michael M. Opata, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G22, Rockville, MD
20852, 240–627–3319, michael.opata@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 11, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–00774 Filed 1–16–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Notice of
Closed Meetings
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Surgical Sciences,
Biomedical Imaging and Bioengineering
Integrated Review Group; Surgery,
Anesthesiology and Trauma Study Section.
Date: February 7–8, 2024.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
18:14 Jan 16, 2024
Jkt 262001
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Weihua Luo, MD, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5114,
MSC 7854, Bethesda, MD 20892, (301) 435–
1170, luow@csr.nih.gov.
Name of Committee: Brain Disorders and
Clinical Neuroscience Integrated Review
Group; Pathophysiological Basis of Mental
Disorders and Addictions Study Section.
Date: February 7–8, 2024.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Boris P. Sokolov, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5217A,
MSC 7846, Bethesda, MD 20892, 301–408–
9115, bsokolov@csr.nih.gov.
Name of Committee: Surgical Sciences,
Biomedical Imaging and Bioengineering
Integrated Review Group; Imaging Probes and
Contrast Agents Study Section.
Date: February 8–9, 2024.
Time: 7:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: DoubleTree McLean Tysons, 1960
Chain Bridge Road, McLean, VA 22101.
Contact Person: Donald Scott Wright,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5108,
MSC 7854, Bethesda, MD 20892, (301) 435–
8363, wrightds@csr.nih.gov.
Name of Committee: Biological Chemistry
and Macromolecular Biophysics Integrated
Review Group; Macromolecular Structure
and Function C Study Section.
Date: February 8–9, 2024.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Bethesdan Hotel, 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Guillermo Andres
Bermejo, Ph.D., Scientific Review Officer,
The Center for Scientific Review, The
National Institutes of Health, 6701 Rockledge
Drive, Bethesda, MD 20892, (301) 827–5742,
bermejog@mail.nih.gov.
Name of Committee: Biology of
Development and Aging Integrated Review
Group; Mechanisms of Cancer Therapeutics
B Study Section.
Date: February 8–9, 2024.
Time: 8:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6705 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Maria Dolores Arjona
Mayor, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Room 806D, Bethesda, MD 20892, (301) 827–
8578, dolores.arjonamayor@nih.gov.
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
Name of Committee: Integrative,
Functional and Cognitive Neuroscience
Integrated Review Group; Sensory-Motor
Neuroscience Study Section.
Date: February 8–9, 2024.
Time: 8:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency, Bethesda One,
Bethesda Metro Center, Bethesda, MD 20814.
Contact Person: Alena Valeryevna
Savonenko, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Room 1009J, Bethesda, MD 20892, (301) 594–
3444, savonenkoa2@csr.nih.gov.
Name of Committee: Endocrinology,
Metabolism, Nutrition and Reproductive
Sciences Integrated Review Group; Basic
Mechanisms of Diabetes and Metabolism
Study Section.
Date: February 8–9, 2024.
Time: 8:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites—Old Town
Alexandri,a Hilton Alexandria Old Town, VA
22314.
Contact Person: Baskaran Thyagarajan,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 800B,
Bethesda, MD 20892, (301) 594–0331,
BASKI.THYAGARAJAN@NIH.GOV,
Name of Committee: Biobehavioral and
Behavioral Processes Integrated Review
Group; Language and Communication Study
Section.
Date: February 8–9, 2024.
Time: 8:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Washington Plaza Hotel, 10 Thomas
Circle NW, Washington, DC 20005.
Contact Person: Rochelle Francine
Hentges, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Room 1000C, Bethesda, MD 20892, (301)
402–8720, hentgesrf@mail.nih.gov.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Kidney Endocrine and Digestive Disorders
Study Section.
Date: February 8–9, 2024.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Steven M. Frenk, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3141,
Bethesda, MD 20892, (301) 480–8665,
frenksm@mail.nih.gov.
Name of Committee: Vascular and
Hematology Integrated Review Group;
Atherosclerosis and Vascular Inflammation
Study Section.
Date: February 8–9, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\17JAN1.SGM
17JAN1
]]>Agencies
[Federal Register Volume 89, Number 11 (Wednesday, January 17, 2024)]
[Notices]
[Pages 2967-2968]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-00774]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which
[[Page 2968]]
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2024-1 Phase
I: Adjuvant Development for Vaccines for Infectious and Immune-
Mediated Diseases (Topic 128).
Date: February 8-9, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G22,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Michael M. Opata, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G22,
Rockville, MD 20852, 240-627-3319, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: January 11, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-00774 Filed 1-16-24; 8:45 am]
BILLING CODE 4140-01-P
